Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study
Nobukazu Fujimoto, Ayumi Akamatsu, Chikara Honda, Miki Aoki, Yuichiro Ohe · 2024
Read Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study by Nobukazu Fujimoto, Ayumi Akamatsu, Chikara Honda, Miki Aoki, Yuichiro Ohe (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11631123.txt.
Description
Nobukazu Fujimoto and co-authors track real-world safety of an immune drug in a rare chest cancer in a 2024 study. The drug, nivolumab, treats malignant pleural mesothelioma after first chemo fails. Regulators in Japan required a post-marketing watch on everyday patients.
The watch enrolled 124 patients at forty-eight sites from 2018 to 2021, with six months of follow-up. About forty percent had treatment-related side effects, and about thirteen percent had severe ones. Lung inflammation was the most common severe effect. The pattern matched the earlier phase two trial, with no new safety signals. Side effects ran higher in inpatients and in patients with autoimmune disease or higher body weight. About a third of patients stayed on therapy at six months.
Catalog record
| CREATOR | Nobukazu Fujimoto, Ayumi Akamatsu, Chikara Honda, Miki Aoki, Yuichiro Ohe |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |